Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP1.4979 placebo-controlled phase 2a trial in adults with obsessive-compulsive disorder
2025-522026-13-00Phase 2Authorised
- Sponsor
- Bioprojet
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing BP1.4979 with Matching placebo (2 arms). Primary endpoint: Change in Yale-Brown Obsessive-Compulsive Scale Second Edition total score. Planned start Jan 2026; status: authorised.
02
Drugs
BP-1.4979
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2025-522026-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522026-13-00.